Mayukh Sukhatme sold $11M of ROIV
Pres&Chief Investment Officer at Roivant Sciences Ltd.. 886,237 shares at an average of $12.01, traded Dec 23, 2024, filed Dec 26, 2024.
Score components
- +15RoleOfficer
- +25Trade size$10.6M at market
- 0Share of holdings soldSold 4.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-24-050461, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | MOption exercise Common Shares | +10,796 | $3.85 | $42k | 18,847,343 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Shares | -10,796 | $12.00 | $130k | 18,836,547 | Dec 26, 2024 |
| Dec 24, 2024 | MOption exercise Common Shares | +185,946 | $3.85 | $716k | 19,022,493 | Dec 26, 2024 |
| Dec 24, 2024 | SOpen-market sale Common Shares | -185,946 | $12.00 | $2.2M | 18,836,547 | Dec 26, 2024 |
| Dec 26, 2024 | MOption exercise Common Shares | +689,495 | $3.85 | $2.7M | 19,526,042 | Dec 26, 2024 |
| Dec 26, 2024 | SOpen-market sale Common Shares | -689,495 | $12.01 | $8.3M | 18,836,547 | Dec 26, 2024 |
| Dec 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -10,796 | $0.00 | $0 | 16,099,804 | Dec 26, 2024 |
| Dec 24, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -185,946 | $0.00 | $0 | 15,913,858 | Dec 26, 2024 |
| Dec 26, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -689,495 | $0.00 | $0 | 15,224,363 | Dec 26, 2024 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 45Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $29M 1,330,868 shares | -7% | |
| 67Notable | Roivant Sciences Ltd. | Richard Pulik CFO | $9.1M 406,731 shares | -63% | |
| 55Moderate | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $6.2M 275,000 shares | -15% | |
| 40Moderate | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $620k 26,831 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.